Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBT Margin (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBT Margin for 15 consecutive years, with 24.96% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 835.0% to 24.96% in Q3 2025 year-over-year; TTM through Sep 2025 was 14.14%, a 6487.0% increase, with the full-year FY2024 number at 15.28%, up 8312.0% from a year prior.
  • EBT Margin was 24.96% for Q3 2025 at Gyre Therapeutics, up from 8.36% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 45.93% in Q1 2024 to a low of 1830.73% in Q1 2022.
  • A 5-year average of 425.64% and a median of 4.92% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: plummeted -150359bps in 2021, then soared 183183bps in 2023.
  • Gyre Therapeutics' EBT Margin stood at 848.75% in 2021, then surged by 97bps to 22.46% in 2022, then plummeted by -1100bps to 269.61% in 2023, then surged by 101bps to 2.39% in 2024, then skyrocketed by 946bps to 24.96% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EBT Margin are 24.96% (Q3 2025), 8.36% (Q2 2025), and 21.01% (Q1 2025).